DAS 181

Drug Profile

DAS 181

Alternative Names: DAS 181-F02; DAS181; DAS181-F04; Fludase; NEX DAS181; ParaDase

Latest Information Update: 25 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NexBio
  • Developer Ansun Biopharma; NexBio
  • Class Antivirals; Recombinant fusion proteins
  • Mechanism of Action Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Parainfluenza virus infections
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Influenza virus infections; Parainfluenza virus infections
  • Preclinical Enterovirus infections; Polyomavirus infections
  • Research Metapneumovirus infections; Respiratory syncytial virus infections
  • No development reported Asthma

Most Recent Events

  • 01 May 2017 Ansun completes a phase II trial in Parainfluenza virus infections (In adolescents, In adults, In the elderly) in USA (Inhalation, Powder and Liquid) (NCT01924793)
  • 15 Dec 2016 Ansun Biopharma completes a phase II trial for Parainfluenza virus infections in USA (NCT01644877)
  • 27 Sep 2016 Early research in Metapneumovirus-infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top